Osteoclastomas or brown tumours are named as such due to increased vascularity, subsequent haemorrhage and haemosiderin deposition giving the lesion a reddish brown appearance under gross microscopic examination. It is due to an increase in parathyroid hormone activity from several causes, such as parathyroid adenomas, renal impairment and low vitamin D levels. The lesions increase the tendency of the bone to fracture. The challenging aspect of the diagnosis is that a histological diagnosis without immunohistochemistry is impossible to make. This is because, without special staining, brown tumours cannot be differentiated from giant cell tumours, which are also classed as benign but can be locally destructive and has potential for malignant transformation. Once tissue diagnosis is confirmed as a brown tumour, then aggressive forms of treatment are not needed, and they generally resolve once the underlying cause is treated. We describe a woman in her 80s who presented to the local Orthopaedic service with a pathological ankle fracture due to a brown tumour.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644310PMC
http://dx.doi.org/10.1136/bcr-2022-251726DOI Listing

Publication Analysis

Top Keywords

brown tumour
12
pathological ankle
8
ankle fracture
8
fracture brown
8
parathyroid hormone
8
brown tumours
8
brown
6
tumour atypical
4
atypical presentation
4
presentation low
4

Similar Publications

Background: In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This review examines oncological endpoints in CC clinical trials.

View Article and Find Full Text PDF

NF2-related schwannomatosis: A view from within the inner ear.

Hear Res

February 2025

UCL Ear Institute, University College London, 332 Gray's Inn Road, London, WC1X 8EE, UK. Electronic address:

NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) is an autosomal dominant disorder associated with the growth of bilateral schwannomas on the cochleo-vestibular nerves and meningiomas. NF2-SWN is caused by pathogenic variations in the NF2, moesin-ezrin-radixin-like (MERLIN) tumour suppressor gene. The mostly benign tumours can cause progressive sensorineural hearing loss, tinnitus and balance dysfunction.

View Article and Find Full Text PDF

Giant cell tumour of bone (GCTB) is viewed as a benign, locally aggressive primary bone tumour with metastatic potential. Current management is surgery with bone curettage or resection and systemic therapy with denosumab. Diagnosis is confirmed histologically prior to surgery, with staging for pulmonary disease, as pulmonary metastases (PM) reportedly occur in <8%.

View Article and Find Full Text PDF

Purpose: The aim of this study is to assess inter-observer variability of the Krenning Score for 99mTc-EDDA/HYNIC-TOC single photon emission computed tomography (SPECT)-computed tomography (CT) images and compare against quantitative metrics obtained from tumour and physiological uptake measurements.

Methods: Thirty-two patients with 117 lesions visible on 99mTc-EDDA/HYNIC-TOC SPECT-CT were scored by two expert observers using the Krenning Score. Five observers with less extensive experience also scored the lesions on visual assessment.

View Article and Find Full Text PDF

Introduction: Oligodendroglioma (ODG) is a rare type of brain tumour, typically diagnosed in younger adults and associated with prolonged survival following treatment. The current standard of care is maximal safe debulking surgery, radiotherapy (RT) and adjuvant procarbazine, lomustine and vincristine (PCV) chemotherapy. Patients may experience long-term treatment-related toxicities, with RT linked to impairments of neurocognitive function (NCF) and health-related quality of life (HRQoL).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!